4D Molecular Therapeutics (FDMT) Payables (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Payables data on file, last reported at $14.7 million in Q1 2026.

• On a quarterly basis, Payables rose 253.94% year-over-year to $14.7 million in Q1 2026; TTM through Mar 2026 was $14.7 million, a 253.94% increase from a year earlier, with the FY2025 full-year figure at $11.2 million, up 154.42% from the prior year.
• Payables for Q1 2026 stood at $14.7 million, up from $11.2 million in the prior quarter.
• Over the last five years, Payables for FDMT reached as high as $14.7 million in Q1 2026 and fell as low as $1.5 million in Q3 2022.
• Historically, Payables has averaged $5.0 million across 5 years, with a median of $3.5 million in 2023.
• Across the five-year window, Payables sank 60.14% in 2022 and jumped 253.94% in 2026, its largest moves.
• Year by year, Payables stood at $3.3 million in 2022, then advanced by 5.81% to $3.5 million in 2023, then grew by 24.78% to $4.4 million in 2024, then jumped by 154.42% to $11.2 million in 2025, then surged by 31.66% to $14.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $14.7 million in Q1 2026, $11.2 million in Q4 2025, and $6.9 million in Q3 2025.